Impax Pharmaceuticals Inc.

Christopher J. Mengler joined us in January 2008 as President, Global Pharmaceuticals, Inc. Before joining us he was most recently Executive Vice President, Global Strategic Planning at Barr Laboratories, Inc., a specialty pharmaceutical company. Mr. Mengler joined Barr in 2002 as Vice President, Strategic Planning and was named Senior Vice President in 2005. Prior to joining Barr, Mr. Mengler was Director, Project Management at Pfizer, Inc. Prior to Pfizer, he served as Director of Planning and Logistics for Barr Laboratories, Inc. and held a number of increasingly responsible positions within the Sales and Marketing department. Mr. Mengler received a Bachelors of Science (BS) in Mathematical Sciences/Operations Research from the Johns Hopkins University, and a BS in Pharmacy from St. John's University College of Pharmacy and Allied Health Professionals. He later received his MBA in Marketing/Finance from Baruch College. Mr. Mengler is a registered pharmacist in New York and Florida, and is a practicing pharmacist in New York. He is also a current member of numerous pharmacist and pharmaceutical associations, including the American Pharmacists Association and the Rho Chi Pharmaceutical Honor Society.

Michael J. Nestor joined us in March 2008 as the President of our newly formed branded products division, Impax Pharmaceuticals. Before joining us he was Chief Operating Officer of Piedmont Pharmaceuticals a specialty pharmaceutical company. Prior to Piedmont, Mr. Nestor was CEO of NanoBio a startup biopharmaceutical company, prior to which he was employed by Alpharma, initially as President of its generic pharmaceutical business and later as President of its branded pharmaceutical business. Before this he was President, International business at Banner Inc, a global contract manufacturing concern. Mr. Nestor spent 16 years at Lederle Laboratories/ Wyeth holding increasing positions of responsibility including Vice President, Cardiovascular business, Vice President/ General Manager of Lederle-Praxis Biologics, and Vice President/ General Manager of Wyeth-Lederle Vaccines and Pediatrics. Mr. Nestor has experience in a number of pharmaceutical therapeutic areas including vaccines, cardiovascular products, anti-infectives, dermatologics, CNS, generics and analgesics. Mr. Nestor has a bachelor of Business Administration degree from Middle Tennessee State University and a MBA from Pepperdine University.

Mr. Doll has been Executive Vice President, Commercial Operations since February 2006. Prior to that he served as the Company's Senior Vice President, Sales and Marketing since joining the Company in March 2001. From June 1993 until February 2001, Mr. Doll served in a number of management functions at Merck & Co., Inc. such as: Senior Director - Managed Care, General Manager - West Point Pharma and Director of Marketing - West Point Pharma. From December 1984 until June 1993, Mr. Doll held a number of sales and marketing management positions at Lemmon Company, a division of Teva Pharmaceutical. Mr. Doll has a B.S. in Commerce from Rider University as well as an MBA in Pharmaceutical Marketing from Saint Joseph's University.

Mr. Hildenbrand is our Senior Vice President, Operations, a position he has held since he joined Impax in September 2004. From 1996 until September 2004, Mr. Hildenbrand worked for the PF Laboratories, Inc. as Plant Manager until 2001, and then as Executive Director of Engineering and Technical Services. From 1983 until 1996, Mr. Hildenbrand worked at Lederle Laboratories/Wyeth as Section Head of Biochemical Production, Manager of Filing and Packaging, and then Production Director of Consumer Health Products. Mr. Hildenbrand holds a B.S. in Chemical Engineering from Villanova University, as well as an MBA from Lehigh University.

Charles Hsiao, Ph.D. has been Chairman and a Director of the Company since December 14, 1999. Since January 1, 2004, Dr. Hsiao has also been leading IMPAX Technologies, a division of IMPAX Laboratories, Inc. In addition, Dr. Hsiao was Co-Chief Executive Officer of the Company from 1999 to 2003. Dr. Hsiao co-founded Impax Pharmaceuticals, Inc. in 1994, and served as its Chairman, Chief Executive Officer and a Director from its inception. Dr. Hsiao co-founded IVAX Corporation in 1986 with two partners. By October 1994, when he left the Vice-Chairman position at IVAX, this company had become the world's largest generic pharmaceutical company with approximately 7,000 employees and $1 billion in worldwide sales. Dr. Hsiao's technical expertise is in the area of formulation and development of oral controlled-release dosage forms. Dr. Hsiao obtained his Ph.D. in pharmaceutics from the University of Illinois.

Leslie Z. Benet, Ph.D . has been a Professor since 1969 of, and has also served as Chairman of, the Department of Biopharmaceutical Sciences, University of California, San Francisco. Dr. Benet has since 1995 been Chairman, President or Chief Executive Officer of AvMax Inc., a biopharmaceutical company. He received his A.B. (English), B.S. (Pharmacy), and M.S. from the University of Michigan, and his Ph.D. from the University of California. Dr. Benet has received six honorary doctorates: Uppsala University, Sweden (Pharm.D., 1987); Leiden University, The Netherlands (Ph.D., 1995); University of Illinois at Chicago (D.Sc., 1997); Philadelphia College of Pharmacy and Science (D.Sc., 1997); Long Island University (D.Sc., 1999); and University of Athens (Ph.D., 2005). Dr. Benet s research interests, more than 470 publications, and 11 patents are in the areas of pharmacokinetics, biopharmaceutics, drug delivery, and pharmacodynamics. He is listed among the 250 most highly cited pharmacologists worldwide. In 1985, Dr. Benet served as President of the APhA Academy of Pharmaceutical Sciences. During 1986, Dr. Benet was a founder and first President of the American Association of Pharmaceutical Scientists (AAPS). In 1987, Dr. Benet was elected to membership in the Institute of Medicine (IOM) of the National Academy of Sciences. Dr. Benet has received the highest scientific awards of AAPS (1989 and 2000), Rho Chi (1990), American Association of Colleges of Pharmacy (1991), American Society for Clinical Pharmacology and Therapeutics (1995), American Pharmaceutical Association (2000), International Pharmaceutical Federation (2001) and in 2004 received the Pharmaceutical Sciences World Congress Research Achievement Award and the Controlled Release Society Career Achievement in Oral Drug Delivery Award. Dr. Benet formerly served as Chair of the FDA Expert Panel on Individual Bioequivalence and the FDA Center for Biologics Peer Review Committee, and as a member of the FDA Science Board and the Generic Drugs Advisory Committee. Dr. Benet presently serves as a member of the IOM Forum on Drug Discovery, Development and Translation.

Mr. Terreri has over 20 years of experience primarily in generic pharmaceuticals with a specialized expertise in finance. Currently he is President & CEO of CGM, Inc., a manufacturing company that he owns and operates and is responsible for all functional areas of the business. Prior to CGM, Mr. Terreri was Senior Vice President and Chief Financial Officer of Teva Pharmaceuticals USA from 1985 to 2000 where he actively participated in the growth of Teva from a $20 million local generic pharmaceutical company into a global leader in generic pharmaceuticals. As an active member of senior management, he was involved in all facets of decisions within Teva, including structuring and negotiating company and product acquisitions, participating in multiple public financings, and securing several licensing deals and a substantial credit line. In addition to his role as CFO, Mr. Terreri contributed to many areas related to the Company's success outside of finance, including product development selection, facility utilization, business development, strategic planning and implementing integration plans for the Company's acquisitions. He also supervised areas such as operations, sales and marketing, and information technology during his tenure.

Bob Burr has been a Director of the Company since August 1999. Mr. Burr has been a Partner of Windcrest Discovery Investments LLC, an investment management firm, from its inception in February 2002 and since October 2001 has a consulting agreement with J.P. Morgan Partners under which he is the lead partner of Fleming US Discovery Partners, L.P., a private equity sponsor affiliated with J.P. Morgan Chase & Co. Fleming US Discovery Partners, L.P. is the general partner of Fleming US Discovery Fund III, L.P. and Fleming US Discovery Offshore Fund III, L.P. Mr. Burr was employed by J. P. Morgan Chase & Co. from July 1995 to October 2001. From 1992 to 1995, Mr. Burr was head of Private Equity at Kidder, Peabody & Co., Inc. Previously, Mr. Burr served as the Managing General Partner of Morgan Stanley Ventures and General Partner of Morgan Stanley Venture Capital Fund I, L.P. and was a corporate lending officer with Citibank, N.A. Mr. Burr serves on the Board of Directors of Displaytech, Inc. and Impax Laboratories, Inc.